Drugging the undruggable with mRNA technology: A new treatment for liver cancer (2024)

Cancer is caused by the hyperactivity of genes that are difficult to drug. Utilising the unique ability of mRNAs to deliver peptides inside cells, this project aims to develop specific inhibitors of these hyperactive genes to treat liver cancer. After further preclinical evaluation the candidates identified here could form the basis of clinical trials and research commercialisation. The approach pioneered through this project can also be applied to diverse targets and human diseases. Executing this research program will help establish me as a national leader in mRNA drug development, underpin competitive funding applications and facilitate and strengthen industry collaborations.